clinical trial · NCT06397274
Stemchymal® for Polyglutamine Spinocerebellar Ataxia
Steminent US, Inc.·phase2·not yet recruiting·n = 20
Spinocerebellar AtaxiasStemchymalPlacebo
brief summary
The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.
started
Jun 1, 2025
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
May 2, 2024
official title
A Phase II, Randomized, Double-Blind, Placebo-controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal (Allogeneic Adipose-derived Mesenchymal Stem Cells) Infusion for the Treatment of PolyQ Spinocerebellar Ataxia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol